atHeart Medical

atHeart Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

atHeart Medical is a clinical-stage medical device innovator targeting the structural heart disease market with its novel reSept™ ASD Occluder. The device's key differentiator is its metal-free frame, aiming to set a new standard of care by minimizing the permanent implant footprint and reducing potential long-term complications like erosion, while not limiting future transseptal interventions. The company is currently advancing its pivotal ASCENT ASD IDE trial in the US and internationally, backed by an experienced leadership team and foundational support from its Swiss corporate founder.

Cardiovascular

Technology Platform

Metal-free frame platform for transcatheter structural heart devices, designed to minimize permanent implant footprint and preserve future treatment options.

Funding History

2
Total raised:$30M
Series B$22M
Series A$8M

Opportunities

The reSept device's metal-free frame addresses unmet needs in ASD closure, particularly for pediatric/young adult patients and those requiring future cardiac interventions, potentially capturing share in a mature market.
The platform technology could also be expanded to other structural heart applications, such as PFO closure.

Risk Factors

The company faces significant clinical risk as its entire value depends on the success of its single pivotal trial.
Post-approval, it must overcome commercial challenges in a market dominated by large, established competitors with deep physician relationships.

Competitive Landscape

The ASD occluder market is dominated by large players like Abbott (Amplatzer) and Occlutech, which offer metal-based devices. atHeart Medical's primary competitive advantage is its novel metal-free design, positioning it as a potential disruptor targeting specific patient subgroups underserved by current technologies.